CryoCath reports 100% acute success for Artic Front catheter

By Elaine Rigoli

Tampa, Fla., June 19 - CryoCath Technologies, Inc. said independent, peer-reviewed data on the company's proprietary Arctic Front catheter to treat paroxysmal atrial fibrillation (AF) showed 100% acute success, as measured by the compete electrical isolation of the pulmonary veins, following ablation on 26 patients treated for paroxysmal AF.

The company said 80% of the pulmonary veins were isolated using Arctic Front only.

The company added that 87% of the 15 patients who have now reached the three-month follow up point were AF free and off all anti-arrhythmic drugs.

No stenosis, thrombosis, esophageal perforation or stroke were reported. Three cases of phrenic nerve palsy were reported, all of which resolved, according to a news release.

Arctic Front is approved for use in Europe; in the United States, Arctic Front is being evaluated in an Investigational Device Exemption feasibility study.

CryoCath recently said it is expanding this trial by 15 additional patients and enrollment of these patients is proceeding as planned.

CryoCath is a medical technology company located in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.